bluuebunny/crossref_metadata_2025_split huggingface dataset:
Acute Effect of Upper and Lower Body Postactivation Exercises on Shot Put Performance
Authors: Kontou Eleni I. , Berberidou Fani T. , Pilianidis Theophilos C. , Mantzouranis Nikolaos I. , Methenitis Spyridon K. 
Published: May 2017

Abstract
Kontou, EI, Berberidou, FT, Pilianidis, TC, Mantzouranis, NI, and Methenitis, SK. Acute effect of upper and lower body postactivation exercises on shot put performance. J Strength Cond Res 32(4): 970–982, 2018—The purpose of this study was to investigate the effect of different types of upper and lower' extremities exercises on acute increase of shot put performance, in moderate experienced throwers. Eight (n = 8) males and 9 (n = 9) female throwers participated in this study. Their bench press and squat maximum strength were measured while their shot put performance from power position was evaluated before and after 4 interventions: (a) plyometric push-ups (Plyo), (b) 6 s isometric push-ups (Iso), (c) 3 countermovement jumps (CMJs) and (d) 10 reps. of skipping (Skip). Interventions were performed in counterbalanced order with a 48-hour interval. Significant increase (p < 0.05) of shot put performances was observed after Plyo, Iso, and CMJ (range: 2.30 ± 1.82%–5.72 ± 4.32%). In addition, Iso induced the highest increase while Skip did not induce any improvement of throwing performance. The highest increases were recorded in men's performance after CMJ (5.72 ± 4.32%) while in women's performance after Iso (3.59 ± 2.7%). Javelin and discus throwers increase higher their performance after CMJs while shot putters after Iso. Significant correlations were found between training experience, maximum/relative strength, shot put performance and increase of throwing performance (%) after the interventions (r: 0.519–0.991, p < 0.05). Percentage increase of performance between Iso and Plyo have negative correlations (r: −0.569, p < 0.05) in contrast of those between Skip and CMJ (r: 0.710, p < 0.05). These results suggest that upper or lower body postactivation interventions may acutely increase the throwing performance. However, experience and strength are significant determinant of this increase.
Effects of Two Combined Exercise Designs Associated With High-Fat Meal Consumption on Postprandial Lipemia, Insulinemia, and Oxidative Stress
Authors: Farinha Juliano B. , Macedo Carlos Ernani O. , Rodrigues-Krause Josianne , Krüger Renata L. , Boeno Francesco P. , Macedo Rodrigo C.O. , Queiroz Jéssica N. , Teixeira Bruno C. , Reischak-Oliveira Alvaro 
Published: May 2017

Abstract
Farinha, JB, Macedo, CEO, Rodrigues-Krause, J, Krüger, RL, Boeno, FP, Macedo, RCO, Queiroz, JN, Teixeira, BC, and Reischak-Oliveira, A. Effects of two combined exercise designs associated with high-fat meal consumption on postprandial lipemia, insulinemia, and oxidative stress. J Strength Cond Res 32(5): 1422–1430, 2018—Impaired postprandial lipemia (PPL) response after the consumption of a high-fat meal (HFM) is linked to diabetes, oxidative stress, and cardiovascular events. The aim of this study was to investigate lipid and glucose metabolism and oxidative stress responses of 2 different combined exercise designs associated with HFM consumption. Eleven healthy and physically active men (27.36 ± 5.04 years) participated in this study. After the pretrial visits, participants were randomly assigned to perform 2-day trials in 3 different conditions (interspaced by at least 1 week): resting (REST), circuit combined exercise (CIRC), or traditional combined exercise (COMB), on the evening of day 1. On the morning of day 2, an HFM was provided and blood samples were obtained before and after 1, 3, and 5 hours of HFM consumption. No differences were found with respect to glucose, thiobarbituric acid–reactive substances, or total thiol levels in between time points or conditions. One-way analysis of variance demonstrated a difference between REST and CIRC (p = 0.029; reduction of 35.29%) and between REST and COMB (p = 0.041; reduction of 33.41%) conditions with incremental area under the curve (iAUC) for triacylglycerol levels. A difference between REST and CIRC (p = 0.03; reduction of 34.22%) conditions in terms of iAUC for insulin was also found. Both CIRC and COMB exercise designs can reduce PPL associated with HFM consumption. Moreover, CIRC reduces the iAUC for insulin, suggesting additional benefits for prescribing this type of exercise.
A Comparison of Load-Velocity and Load-Power Relationships Between Well-Trained Young and Middle-Aged Males During Three Popular Resistance Exercises
Authors: Fernandes John F.T. , Lamb Kevin L. , Twist Craig 
Published: May 2017

Abstract
Fernandes, JFT, Lamb, KL, and Twist, C. A comparison of load-velocity and load-power relationships between well-trained young and middle-aged males during 3 popular resistance exercises. J Strength Cond Res 32(5): 1440–1447, 2018—This study examined the load-velocity and load-power relationships among 20 young (age 21.0 ± 1.6 years) and 20 middle-aged (age 42.6 ± 6.7 years) resistance-trained males. Participants performed 3 repetitions of bench press, squat, and bent-over-row across a range of loads corresponding to 20–80% of 1 repetition maximum (1RM). Analysis revealed effects (p < 0.05) of group and load × group on barbell velocity for all 3 exercises, and interaction effects on power for squat and bent-over-row (p < 0.05). For bench press and bent-over-row, the young group produced higher barbell velocities, with the magnitude of the differences decreasing as load increased (ES; effect size 0.0–1.7 and 1.0–2.0, respectively). Squat velocity was higher in the young group than the middle-aged group (ES 1.0–1.7) across all loads, as was power for each exercise (ES 1.0–2.3). For all 3 exercises, both velocity and 1RM were correlated with optimal power in the middle-aged group (r = 0.613–0.825, p < 0.05), but only 1RM was correlated with optimal power (r = 0.708–0.867, p < 0.05) in the young group. These findings indicate that despite their resistance training, middle-aged males were unable to achieve velocities at low external loads and power outputs as high as the young males across a range of external resistances. Moreover, the strong correlations between 1RM and velocity with optimal power suggest that middle-aged males would benefit from training methods which maximize these adaptations.
Seasonal Variations of Bone Metabolism and Bone Mineral Density in Collegiate Alpine Skiers
Authors: Sato Teruyuki , Sakuraba Keishoku , Tsuchiya Yosuke , Maruyama Shinya , Ochi Eisuke 
Published: May 2017

Abstract
Sato, T, Sakuraba, K, Tsuchiya, Y, Maruyama, S, and Ochi, E. Seasonal variations of bone metabolism and bone mineral density in collegiate alpine skiers. J Strength Cond Res 32(5): 1448–1454, 2018—This study investigated the seasonal variations in bone metabolism, mineral density, and physical characteristics in collegiate alpine skiers. Twelve male subjects (20.6 ± 1.5 years) were evaluated for body composition, bone mineral density (BMD), serum levels of osteocalcin (OC), bone alkaline phosphatase (BAP), tartrate-resistant acid phosphatase 5b (TRACP-5b), parathormone, and 25-hydroxy vitamin D. We also measured the knee extensor and flexor strength, maximal power, and vertical jump. Measurements were conducted in the preseason period (T1), competitive period (T2), end-of-season period (T3), and resting period (T4). The percentage of body fat significantly increased from T1 to T2—T4 (p < 0.05), but lean body mass significantly decreased from T1 to T2—T4 (p < 0.05). Although BMD increased at T2 (0.9%) and T3 (0.8%), as compared with that at T1 (p < 0.05), BAP and OC decreased at T2 and T3, as compared with that at T1 (p < 0.05). Tartrate-resistant acid phosphatase 5b significantly increased from T1 to T2 (p < 0.05). We concluded that it is important to monitor bone metabolism markers and BMD of male alpine skiers throughout the season.
Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma
Authors: Rao Dipti , Peitzsch Mirko , Prejbisz Aleksander , Hanus Katarzyna , Fassnacht Martin , Beuschlein Felix , Brugger Christina , Fliedner Stephanie , Langton Katharina , Pamporaki Christina , Gudziol Volker , Stell Anthony , Januszewicz Andrzej , Timmers Henri J L M , Lenders Jacques W M , Eisenhofer Graeme 
Published: May 2017

ContextMeasurements of plasma methoxytyramine, the O-methylated dopamine metabolite, are useful for detecting rare dopamine-producing pheochromocytomas and paragangliomas (PPGLs) and head and neck paragangliomas (HNPGLs), but utility for screening beyond that achieved using standard measurements of normetanephrine and metanephrine is unclear.ObjectiveEvaluation of the additional utility of methoxytyramine compared to plasma normetanephrine and metanephrine for diagnosis of PPGLs and HNPGLs.DesignComparative prospective study.MethodsComparison of mass spectrometric-based measurements of plasma methoxytyramine, normetanephrine and metanephrine in 1963 patients tested for PPGLs at six tertiary medical centers according to reference intervals verified in 423 normotensive and hypertensive volunteers.ResultsOf the screened patients, 213 had PPGLs and 38 HNPGLs. Using an upper cut-off of 0.10 nmol/L for methoxytyramine, 0.45 nmol/L for metanephrine and age-specific upper cut-offs for normetanephrine, diagnostic sensitivity with the addition of methoxytyramine increased from 97.2% to 98.6% for patients with PPGLs and from 22.1% to 50.0% for patients with HNPGLs, with a small decrease in specificity from 95.9% to 95.1%. Addition of methoxytyramine did not significantly alter areas under receiver operating characteristic curves for patients with PPGLs (0.984 vs 0.991), but did increase (P < 0.05) areas for patients with HNPGLs (0.627 vs 0.801). Addition of methoxytyramine also increased the proportion of patients with PPGLs who showed highly positive predictive elevations of multiple metabolites (70.9% vs 49.3%).ConclusionsWhile the benefit of additional measurements of plasma methoxytyramine for the detection of PPGLs is modest, the measurements do assist with positive confirmation of disease and are useful for the detection of HNPGLs.
A New Method, “Reverse Yeast Two-Hybrid Array” (RYTHA), Identifies Mutants that Dissociate the Physical Interaction Between Elg1 and Slx5
Authors: Lev Ifat , Shemesh Keren , Volpe Marina , Sau Soumitra , Levinton Nelly , Molco Maya , Singh Shivani , Liefshitz Batia , Ben Aroya Shay , Kupiec Martin 
Published: May 2017

Abstract
The vast majority of processes within the cell are carried out by proteins working in conjunction. The Yeast Two-Hybrid (Y2H) methodology allows the detection of physical interactions between any two interacting proteins. Here, we describe a novel systematic genetic methodology, “Reverse Yeast Two-Hybrid Array” (RYTHA), that allows the identification of proteins required for modulating the physical interaction between two given proteins. Our assay starts with a yeast strain in which the physical interaction of interest can be detected by growth on media lacking histidine, in the context of the Y2H methodology. By combining the synthetic genetic array technology, we can systematically screen mutant libraries of the yeast Saccharomyces cerevisiae to identify trans-acting mutations that disrupt the physical interaction of interest. We apply this novel method in a screen for mutants that disrupt the interaction between the N-terminus of Elg1 and the Slx5 protein. Elg1 is part of an alternative replication factor C-like complex that unloads PCNA during DNA replication and repair. Slx5 forms, together with Slx8, a SUMO-targeted ubiquitin ligase (STUbL) believed to send proteins to degradation. Our results show that the interaction requires both the STUbL activity and the PCNA unloading by Elg1, and identify topoisomerase I DNA–protein cross-links as a major factor in separating the two activities. Thus, we demonstrate that RYTHA can be applied to gain insights about particular pathways in yeast, by uncovering the connection between the proteasomal ubiquitin-dependent degradation pathway, DNA replication, and repair machinery, which can be separated by the topoisomerase-mediated cross-links to DNA.
Efeito da terapia LED na disfunção temporomandibular: estudo de caso
Authors: Costa Davidson Ribeiro , Costa David Ribeiro , Pessoa Diego Rodrigues , Masulo Leandro Júnio , Arisawa Emília Ângela Lo Schiavo , Nicolau Renata Amadei 
Published: May 2017

*** Effect of LED therapy on temporomandibular disorder: a case study ***AIMS: To evaluate the effect of light emitting diode (LED) therapy on temporomandibular disorder.CASE DESCRIPTION: A woman diagnosed with temporomandibular disorder was subjected to four LED therapy sessions at a seven-day interval. In the initial examination of the temporomandibular joint the patient presented a mouth opening without pain of 23 mm, a maximum opening of 25 mm and a maximum opening with the aid of 27 mm. After the treatment, there was an increase of 7 mm in the opening without pain between the first and last evaluation, while the maximum opening of the mouth and the maximum opening with aid increased 6 mm between the first and last evaluation. After 21 days of treatment, a 50% reduction in painful sites was detected on the palpation examination. After the end of the treatment, the visual analog pain scale detected a decrease in pain intensity on both sides, and there was a decrease in the total mean pain intensity. By analyzing the responses to the Medical Outcomes Study 36-item Short Form Health Survey (SF-36), of the eight quality of life domains evaluated, four showed improvement. CONCLUSIONS: In this case study, after LED therapy there was reduction in pain intensity and increase of the mandibular range of motion. The resolution of the signs and symptoms of temporomandibular disorder resulted in patient’s better quality of life.
Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy
Authors: Sclafani Francesco , Brown Gina , Cunningham David , Rao Sheela , Tekkis Paris , Tait Diana , Morano Federica , Baratelli Chiara , Kalaitzaki Eleftheria , Rasheed Shahnawaz , Watkins David , Starling Naureen , Wotherspoon Andrew , Chau Ian 
Published: May 2017

Abstract

Background
The potential of chemotherapy as salvage treatment after failure of neoadjuvant chemoradiotherapy for locally advanced rectal cancer (LARC) has never been explored. We conducted a single-center, retrospective analysis to address this question.

Patients and Methods
Patients with newly diagnosed LARC who were inoperable or candidates for extensive (i.e., beyond total mesorectal excision [TME]) surgery after long-course chemoradiotherapy and who received salvage chemotherapy were included. The primary objective was to estimate the proportion of patients who became suitable for TME after chemotherapy.

Results
Forty-five patients were eligible (39 candidates for extensive surgery and 6 unresectable). Previous radiotherapy was given concurrently with chemotherapy in 43 cases (median dose: 54.0 Gy). Oxaliplatin- and irinotecan-based salvage chemotherapy was administered in 40 (88.9%) and 5 (11.1%) cases, respectively. Eight patients (17.8%) became suitable for TME after chemotherapy, 10 (22.2%) ultimately underwent TME with clear margins, and 2 (4.4%) were managed with a watch and wait approach. Additionally, 13 patients had extensive surgery with curative intent. Three-year progression-free survival and 5-year overall survival in the entire population were 30.0% (95% confidence interval [CI]: 15.0–46.0) and 44.0% (95% CI: 26.0–61.0), respectively. For the curatively resected and “watch and wait” patients, these figures were 52.0% (95% CI: 27.0–73.0) and 67.0% (95% CI: 40.0–84.0), respectively.

Conclusion
Systemic chemotherapy may be an effective salvage strategy for LARC patients who fail to respond to chemoradiotherapy and are inoperable or candidates for beyond TME surgery. According to our study, one out of five patients may become resectable or be spared from an extensive surgery after systemic chemotherapy.
Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer
Authors: Abrams Thomas A. , Meyer Gary , Meyerhardt Jeffrey A. , Wolpin Brian M. , Schrag Deborah , Fuchs Charles S. 
Published: May 2017

Abstract

Purpose
Few population studies have examined patterns of systemic therapy administration in metastatic pancreatic cancer (MPC) or the predictors associated with specific treatment choices.

Patients and Methods
We assessed 4,011 consecutive MPC patients who received chemotherapy between January 2005 and December 2015 at academic, private, and community-based oncology practices subscribing to a U.S.-wide chemotherapy order entry system capturing disease, patient, provider, and treatment data. Multivariate analyses of these prospectively recorded characteristics identified significant predictors of specific therapeutic choices.

Results
Overall, 100 different regimens were used in first-line treatment of MPC. First-line gemcitabine monotherapy usage fell steadily from 72% in 2006 to 16% in 2015. This steep decline mirrored increases in first-line usage of both 5 fluorouracil, leucovorin, irinotecan and oxaliplatin (FOLFIRINOX) and gemcitabine + nab-paclitaxel. Younger male patients were more likely to receive FOLFIRINOX as first-line treatment, whereas patients treated at community practices and by oncologists with lower MPC patient volume were more likely to receive gemcitabine plus nab-paclitaxel (all p ≤ .05). Among all patients receiving first-line chemotherapy for MPC, 49% went on to receive second-line therapy and 19% received third-line therapy; administration of second- and third-line therapies increased steadily over the time course of follow-up. Younger patients and those treated by oncologists with higher MPC patient volume were more likely to receive second- and third-line therapies.

Conclusion
This population-based study provides insight into treatment patterns of MPC in the U.S. Usage patterns varied greatly according to patient and provider characteristics.
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma
Authors: Betof Allison S. , Nipp Ryan D. , Giobbie-Hurder Anita , Johnpulle Romany A. N. , Rubin Krista , Rubinstein Samuel M. , Flaherty Keith T. , Lawrence Donald P. , Johnson Douglas B. , Sullivan Ryan J. 
Published: May 2017

Abstract

Background
Monoclonal antibodies (mAb) targeting PD-1/PD-L1 have revolutionized melanoma treatment, yet data regarding effectiveness and tolerability across age groups is limited. We sought to determine the impact of age on overall survival (OS), progression-free survival (PFS), and rates of immune-mediated toxicities in patients treated with anti–PD-1/anti-PD-L1 mAb at two academic medical centers.

Methods
We retrospectively collected data on all patients with metastatic melanoma treated with anti-PD-1/PD-L1 mAb between May 2009 and April 2015. We used Kaplan-Meier and Cox regression analyses to assess OS and PFS and identify factors associated with these outcomes. We also compared rates of autoimmune toxicity across age groups.

Results
Of 254 patients, 57 (22.4%) were &lt;50 years old, 85 (33.5%) were age 50–64, 65 (25.6%) were age 65–74, and 47 (18.5%) were ≥75 years. Across age groups, no differences existed in median OS (age &lt;50: 22.9 months, age 50–64: 25.3 months, age 65–74: 22.0 months, age ≥75: 24.3 months) or PFS (age &lt;50: 4.1 months, age 50–64: 6.5 months, age 65–74: 5.4 months, age ≥75: 7.9 months). The presence of liver metastases and elevated pre-treatment lactate dehydrogenase (LDH) were associated with reduced OS. Presence of liver metastasis, pretreatment LDH, BRAF mutation, and type of melanoma correlated with PFS. Overall, 110 patients (43.3%) experienced immune-mediated toxicities; 25 (9.8%) had colitis and 26 (10.2%) had endocrine toxicity. Rates of colitis, hepatitis, and pneumonitis did not differ across age groups.

Conclusion
We demonstrated that patients could safely tolerate anti-PD1/PDL-1 mAb therapy and achieve similar outcomes regardless of their age.
Implementation of the Edmonton Symptom Assessment System for Symptom Distress Screening at a Community Cancer Center: A Pilot Program
Authors: Hui David , Titus Annie , Curtis Tiffany , Ho-Nguyen Vivian Trang , Frederickson Delisa , Wray Curtis , Granville Tenisha , Bruera Eduardo , McKee Donna K. , Rieber Alyssa 
Published: May 2017

Abstract

Background
Distress screening is mandated by the American College of Surgeons Commission on Cancer; however, there is limited literature on its impact in actual practice. We examined the impact of a pilot distress screening program on access to psychosocial care.

Methods
Edmonton Symptom Assessment System (ESAS) screening was routinely conducted at our community-based medical oncology program. Patients who screened positive for severe distress were sent to a social worker for triage and referred to the appropriate services if indicated. We compared the proportion of patients who had ESAS completed, the proportion of patients who screened positive, and the number of patients who had social work assessment and palliative care consultation over the preimplementation (September 2015), training (October/November 2015), and postimplementation (December 2015) periods.

Results
A total of 379, 328, and 465 cancer patients were included in the preimplementation, training, and postimplementation periods, respectively. The proportion of patients who completed ESAS increased over time (83% vs. 91% vs. 96%). Among the patients who had completed ESAS, between 11% and 13% were positive for severe distress, which remained stable over the three periods. We observed a significant increase in social work referrals for psychosocial assessment (21% vs. 71% vs. 79%). There was also a trend towards an increased number of palliative care referrals (12% vs. 20% vs. 28%).

Conclusion
Our community-based cancer center implemented distress screening rapidly in a resource-limited setting, with a notable increase in symptom documentation and psychosocial referral.